Christian Stegmann

This inventor holds 14 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Stegmann. Retrieved from https://idiyas.com/inventor/christian-stegmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 6)

% Patents Active = 57.1

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 12.4

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

14 out of 387

Bayer Pharma Aktiengesellschaft

patents

1 out of 721

Bayer Intellectual Property Gmbh

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Substituted Indazoles

Pharmaceutical Preparations

Macrocyclic Compounds

Piperidinylpyrazolopyrimidinones

Aza Pyridopyrazolopyrimidinones

3-Substituted Estras

Medicaments

Drug Production

Chemical Synthesis

Indazolopyrimidinones

Sulfondiimine Compounds

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559473 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2026-02-24),

2. 12006304 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

3. 12006303 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs (2024-06-11),

4. 10793545 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2020-10-06),

5. 10717749 - Macrocyclic sulfondiimine compounds (2020-07-21),

6. 10668071 - (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use (2020-06-02),

7. 10308634 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2019-06-04),

8. 10214542 - Modified macrocyclic compounds (2019-02-26),

9. 10118930 - Piperidinylpyrazolopyrimidinones and their use (2018-11-06),

10. 10098883 - (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use (2018-10-16),

11. 9963464 - Macrocyclic compounds (2018-05-08),

12. 9643953 - Substituted benzylpyrazoles (2017-05-09),

13. 9598417 - (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use (2017-03-21),

14. 9512169 - 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments (2016-12-06),

Title: Inventor Christian Stegmann: Innovating Pharmaceutical Solutions in Berlin

Introduction

Christian Stegmann is a prolific inventor based in Berlin, Germany, holding a remarkable total of 13 patents. His inventiveness in the pharmaceutical field has yielded significant advancements, particularly in the treatment of complex medical conditions through innovative drug formulations.

Latest Patents

Among his latest patents, Stegmann has developed methods related to novel substituted indazoles. These patents focus on pharmaceutical preparations containing said substituted indazoles and elucidate their use for the production of drugs aimed at treating various diseases. Notably, these inventions target conditions such as endometriosis and its associated symptoms, which include dysmenorrhoea and dyspareunia, along with a range of other diseases like lymphoma, multiple sclerosis, and psoriasis. The innovative approaches presented in his patent applications highlight the potential for enhanced treatment regimes for patients suffering from these ailments.

Career Highlights

Stegmann has built a distinguished career working with significant companies in the pharmaceutical sector. Notably, he has contributed his expertise at Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His experiences at these leading firms have been instrumental in shaping his research and innovation journey.

Collaborations

Throughout his career, Stegmann has collaborated with talented professionals such as Ulrich Bothe and Ulf Bömer. Working alongside such esteemed colleagues has allowed him to expand his knowledge and refine his innovations, further elevating his impact in the field of pharmaceuticals.

Conclusion

Christian Stegmann's contributions to the pharmaceutical industry through his inventive work on substituted indazoles reflect a deep commitment to improving patient care and addressing complex health challenges. His impressive portfolio of patents and collaborations showcases the innovative spirit that drives advancements in healthcare, positioning him as a notable inventor in the modern scientific landscape.

Profile summary based on public USPTO records.